Copyright
©The Author(s) 2023.
World J Gastroenterol. Jan 14, 2023; 29(2): 223-231
Published online Jan 14, 2023. doi: 10.3748/wjg.v29.i2.223
Published online Jan 14, 2023. doi: 10.3748/wjg.v29.i2.223
Table 2 Indication and contraindications of irreversible electroporation in pancreatic cancer
Indication | Contraindications | |
Absolute | Relative | |
Biopsy-proven primary and solitary pancreatic tumors | History of ventricular arrhythmias | Atrial fibrillation |
Locally advanced pancreatic cancer. Stage II or III (T4N1M0) with regional positive lymph nodes ≤ 3 | Implanted cardiac stimulation devices within 1 yr | Coronary artery disease |
Tumor size maximal axial diameter ≤ 5 cm | Uncontrollable hypertension | Combined severe stenosis of the common hepatic artery and main portal vein branch |
Patients not candidates for radical resection or who refuse the surgical operation | History of epilepsy | Metallic foreign object in the ablation zone |
Patients with a predictable OS longer than 3 mo, Karnofsky Performance Score > 50 | Congestive heart failure (> NHYA class 2) | Liver failure, portal hypertension, ascites, bile duct obstruction, hyperbilirubinemia |
Irreversible bleeding disorders | ||
Uncontrolled infections; patients that have received chemo or immunotherapy in the 4 wk prior to treatment |
- Citation: Spiliopoulos S, Reppas L, Filippiadis D, Delvecchio A, Conticchio M, Memeo R, Inchingolo R. Irreversible electroporation for the management of pancreatic cancer: Current data and future directions. World J Gastroenterol 2023; 29(2): 223-231
- URL: https://www.wjgnet.com/1007-9327/full/v29/i2/223.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i2.223